{
    "clinical_study": {
        "@rank": "78958", 
        "arm_group": [
            {
                "arm_group_label": "BI 860585", 
                "arm_group_type": "Experimental", 
                "description": "Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts"
            }, 
            {
                "arm_group_label": "BI 860585 + paclitaxel", 
                "arm_group_type": "Experimental", 
                "description": "Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel"
            }, 
            {
                "arm_group_label": "BI 860585 + exemestane", 
                "arm_group_type": "Experimental", 
                "description": "Multiple ascending doses of BI 860585 in combination with fixed dose exemestane"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI\n      860585 alone and in combination with exemestane or paclitaxel. To determine the MTDs,\n      patients are entered sequentially into escalating dose cohorts. Secondary objectives are\n      objective response and disease control according to RECIST criteria version 1.1"
        }, 
        "brief_title": "BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with histologically or cytologically confirmed diagnosis of advanced,\n             measurable or evaluable, non-resectable and/or metastatic solid tumours, which has\n             shown to be progressive;\n\n          -  Patients who have received previous standard of care therapy for their disease and\n             have progressed;\n\n          -  18 years or older;\n\n          -  Life expectancy >= 3 months;\n\n          -  Written informed consent in accordance with International Conference on\n             Harmonisation/Good Clinical Practice (ICH/GCP) and local legislation;\n\n          -  Eastern Cooperative Oncology Group (ECOG), performance score 0-2.\n\n        Additional inclusion criteria for the combination arms:\n\n          -  Patients must have confirmed progressive disease within the last 6 months, (in case\n             of measurable disease, progression should be confirmed   according to Response\n             Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1;\n\n          -  Patients carrying a tumour for whom treatment with either exemestane or paclitaxel\n             would be considered appropriate;\n\n        Exclusion criteria:\n\n          -  Serious concomitant non-oncological disease/illness considered by the investigator to\n             be incompatible with the protocol;\n\n          -  Patients with untreated or symptomatic brain metastases;\n\n          -  Second malignancies requiring active therapy;\n\n          -  Clinical Congestive Heart Failure (CHF) Grade III-IV;\n\n          -  Myocardial infarction within the last 6 months prior to inclusion, or symptomatic\n             coronary artery disease;\n\n          -  Adequate bone marrow, liver and renal function;\n\n          -  Patients with HIV/hepatitis/active infectious disease considered by the investigator\n             to be incompatible with the protocol;\n\n          -  Patients unable to take oral medication;\n\n          -  Chronic diarrhoea or other gastrointestinal disorders;\n\n          -  Treatment with cytotoxic anti-cancer-therapies or investigational drugs within four\n             weeks of the first treatment with the study medication (or within one week for\n             noncytotoxic drugs);\n\n          -  Recovery from previous surgery and anticancer medical treatments;\n\n          -  Hypersensitivity to combination drugs or excipients;\n\n          -  Patients with a history of uncontrolled diabetes mellitus."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938846", 
            "org_study_id": "1325.1", 
            "secondary_id": "2013-000765-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 860585 + paclitaxel", 
                "description": "BI 860585 multiple dose escalation,  once daily", 
                "intervention_name": "BI 860585", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 860585 + exemestane", 
                "description": "exemestane once daily", 
                "intervention_name": "exemestane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 860585", 
                "description": "BI 860585 multiple dose escalation, once daily", 
                "intervention_name": "BI 860585", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 860585 + exemestane", 
                "description": "BI 860585 multiple dose escalation,  once daily", 
                "intervention_name": "BI 860585", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 860585 + paclitaxel", 
                "description": "paclitaxel once weekly", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Exemestane", 
                "Paclitaxel"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "1325.1.32001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "1325.1.32002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "1325.1.39001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy"
                    }, 
                    "name": "1325.1.39002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Italy"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal and Health Products", 
                "Italy: The Italian Medicines Agency"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum tolerated dose in each treatment arm (based on number of dose limiting toxicities (DLTs) in first course of each treatment arm.", 
                "safety_issue": "No", 
                "time_frame": "first 28 days of treatment"
            }, 
            {
                "measure": "Number of DLTs in first course of each treatment arm.", 
                "safety_issue": "Yes", 
                "time_frame": "first 28 days of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938846"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC0-infinity of BI 860585 administered as single agent and with combination agents.", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days of treatment"
            }, 
            {
                "measure": "t1/2(ss) of BI 860585 administered as single agent and with combination agents.", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days of treatment"
            }, 
            {
                "measure": "tmax(ss) of BI 860585 administered as single agent and with combination agents.", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days of treatment"
            }, 
            {
                "measure": "Objective response rate (complete response/CR, partial response/PR per RECIST criteria version 1.1).", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Disease control rate/clinical benefit rate (complete response/CR, partial response/PR, stable disease/SD per RECIST criteria version 1.1).", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Duration of objective response (CR/PR), defined as time from first objective response to the time to progression or death.", 
                "safety_issue": "No", 
                "time_frame": "time from first objective response to the time to progression or death, assessed up to 4 months"
            }, 
            {
                "measure": "Duration of clinical benefit (CR/PR/SD), defined as time from first clinical benefit to progression or death.", 
                "safety_issue": "No", 
                "time_frame": "time from first clinical benefit to progression or death, assessed up to 4 months"
            }, 
            {
                "measure": "AUC0-24(ss) of BI 860585 administered as single agent and with combination agents.", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days of treatment"
            }, 
            {
                "measure": "Cmax(ss) of BI 860585 administered as single agent and with combination agents.", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days of treatment"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}